Sonnet biotherapeutics announces regulatory approval for initiation of a clinical trial of son-1010 combined with atezolizumab

Clinical trial was approved by the bellberry human research ethics committee (hrec) in australia the combination of sonnet's son-1010 and roche's atezolizumab (tecentriq®) will be evaluated for the treatment of platinum-resistant ovarian cancer recruitment is being initiated with dosing anticipated to begin imminently princeton, nj / accesswire / june 20, 2022 / sonnet biotherapeutics holdings, inc., (nasdaq:sonn) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a phase 1b/2a clinical trial of son-1010 (il12-fhab) in combination with roche's anti-pd-l1 checkpoint inhibitor, atezolizumab (tecentriq®), has been approved to begin in australia. the approval by the bellberry hrec was based on scientific and ethical review of trial documentation, which included the successful completion of a study of son-1010 monotherapy (sb102) in healthy volunteers (nct05408572) and demonstration of continued safety in the first-in-human (fih) dose-escalation trial in cancer (sb101).
SONN Ratings Summary
SONN Quant Ranking